Skip to content
Screener

Insmed INSM Operating Lease Liabilities

Operating Lease Liabilities at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$198.23M-7.6%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$17.92M-11.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$320K
Theravance Biopharma logo
Theravance BiopharmaTBPH
$29.75M-20.3%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$390K-60.7%
Mannkind logo
MannkindMNKD
$9.69M-9.1%

Other financials

Income statement

See full
Revenue$425.5M+296%
Gross profit$358.3M+352%
Operating income-$1.5M+99.5%
Net income-$13.2M+95.9%
EPS (diluted)-$0.06+96.5%

Balance sheet

See full
Cash & equivalents$544.8M-57.6%
Total debt$579.9M+0.8%
Total equity$757.5M-39.4%
Total assets$2.1B-15.2%

Cash flow

See full
Operating cash flow-$88.8M+56.8%
CapEx$6.3M+79.6%
Free cash flow-$95.1M+54.5%

Valuation

See full
Market cap$28.95B+37.0%
Enterprise value$28.98B+41.9%
P/S25.4×-27.6×

Profitability

See full
Gross margin83.5%+7.7pp
Operating margin-73.9%-30.6pp
Net margin-76.9%-31.8pp
FCF margin-71%-28.6pp

Returns & leverage

See full
Return on equity-87.2%-27.3pp
Debt / equity0.8×+0.3×
Current ratio3.7×-3.0×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Insmed’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104506-26-000041
Line itemAs of / June 30, 2026As of / December 31, 2025
Royalty financing agreement159,843162,865
Contingent consideration170,550314,340
Finance lease liabilities, long-term18,89020,719
Operating lease liabilities, long-term7,66312,174
Other long-term liabilities5,8685,646
Total liabilities1,345,0711,525,582
Shareholders’ equity:
Common stock, $0.01 par value; 500,000,000 authorized shares, 218,281,059 and 214,255,853 issued and outstanding shares at June 30, 2026 and December 31, 2025, respectively2,1832,143

Item 1C. Consolidated Financial Statements

FAQ

What is Insmed's operating lease liabilities?
Insmed (INSM) reported operating lease liabilities of $7.66M in Q2 2026.
How has Insmed's operating lease liabilities changed year-over-year?
Insmed's operating lease liabilities decreased by 3.0% year-over-year, from $7.9M to $7.66M.
What is the long-term trend for Insmed's operating lease liabilities?
Over 5 years (2020 to 2025), Insmed's operating lease liabilities has grown at a -10.5% compound annual growth rate (CAGR), from $21.26M to $12.17M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Insmed's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude